Omalizumab is administered by which route:: (A) Inhalation, (B) Intravenous, (C) Intranasal, (D) Subcutaneous
Answer is D. Patients should be given a 3-4 month trial of therapy to show objective benefit. Omalizumab is usually given as a subcutaneous injection every 2-4 weeks and appears not to have significant side effects. Ref: Harrison's principle of internal medicine 17th edition, chapter 248.